Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Laureen de Bever"'
Autor:
Marloes A. Wijdeven, Remon van Geel, Jorin H. Hoogenboom, Jorge M. M. Verkade, Brian M. G. Janssen, Inge Hurkmans, Laureen de Bever, Sander S. van Berkel, Floris L. van Delft
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Antibody-drug conjugates (ADCs) are increasingly powerful medicines for targeted cancer therapy. Inspired by the trend to further improve their therapeutic index by generation of homogenous ADCs, we report here how the clinical-stage GlycoConnect™
Externí odkaz:
https://doaj.org/article/848d309b246a42aca0115d74462db631
Autor:
Laureen de Bever, Sorraya Popal, Jord van Schaik, Baron Rubahamya, Floris L. van Delft, Greg M. Thurber, Sander S. van Berkel
Publikováno v:
Bioconjugate Chemistry. 34:538-548
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a226ada7c59d0b8e04a021b37862ac2d
https://doi.org/10.1021/acs.bioconjchem.2c00611
https://doi.org/10.1021/acs.bioconjchem.2c00611
Autor:
Greg M. Thurber, Floris L. van Delft, Laureen de Bever, Haolong Huang, Shujun Dong, Eshita Khera
Supplementary DataSupplementary Fig. S1-S21, Table S1-S5
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6e26f9132e8c3cde6ea63db11e3e351
https://doi.org/10.1158/1535-7163.22522801
https://doi.org/10.1158/1535-7163.22522801
Autor:
Eshita Khera, Shujun Dong, Haolong Huang, Laureen de Bever, Floris L. van Delft, Greg M. Thurber
Publikováno v:
Molecular Cancer Therapeutics. 21:310-321
After several notable clinical failures in early generations, antibody–drug conjugates (ADC) have made significant gains with seven new FDA approvals within the last 3 years. These successes have been driven by a shift towards mechanistically infor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f4c9f52164102d03b03221e00038c540
https://doi.org/10.1158/1535-7163.mct-21-0580
https://doi.org/10.1158/1535-7163.mct-21-0580